Search Results

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

Authors: Coma, Anna; Zara, Corinne; Godman, Brian; Agustí, Antònia; Diogène, Eduardo; Wettermark, Björn; Haycox, Alan

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 9, Number 6, December 2009 , pp. 569-581(13)

Publisher: Expert Reviews

Balsalazide in treating colonic diseases

Author: Tursi, Antonio

Source: Expert Opinion on Drug Metabolism and Toxicology, Volume 5, Number 12, December 2009 , pp. 1555-1563(9)

Publisher: Informa Healthcare

Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships

Authors: Hollak, Carla EM; de Fost, Maaike; van Dussen, Laura; vom Dahl, Stephan; Aerts, Johannes MFG

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 16, November 2009 , pp. 2641-2652(12)

Publisher: Informa Healthcare

The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer

Authors: Garrison, Louis P.; Veenstra, David L.

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1118-1123(6)

Publisher: Blackwell Publishing

Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia

Authors: Friedman, Howard; Song, Xue; Crespi, Simone; Navaratnam, Prakash

Source: Value in Health, Volume 12, Number 8, November/December 2009 , pp. 1135-1143(9)

Publisher: Blackwell Publishing

The Future of Health Technology Assessment in Healthcare Decision Making in Asia

Author: Yang, Bong-Min

Source: PharmacoEconomics, Volume 27, Number 11, 1 November 2009 , pp. 891-901(11)

Publisher: Adis International

Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke

Authors: Bath, P. M. W.; Macleod, M. R.; Green, A. R.

Source: International Journal of Stroke, Volume 4, Number 6, December 2009 , pp. 471-479(9)

Publisher: Blackwell Publishing

Cost-Effectiveness Analysis of Oseltamivir for Influenza Treatment Considering the Virus Emerging Resistant to the Drug in Japan

Authors: Nagase, Hiroko; Moriwaki, Kensuke; Kamae, Maki; Yanagisawa, Shinichiro; Kamae, Isao

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S62-S65(1)

Publisher: Blackwell Publishing

A Time-Cost Augmented Economic Evaluation of Oral Deferasirox versus Infusional Dereroxmine for Patients with Iron Overload in South Korea

Authors: Kim, Jinhyun; Kim, Younhee

Source: Value in Health, Volume 12, Supplement 3, November/December 2009 , pp. S78-S81(1)

Publisher: Blackwell Publishing

Empirical therapy for serious Gram-positive infections: making the right choice

Author: Segreti, J.

Source: Clinical Microbiology & Infection, Volume 15, Supplement 6, December 2009 , pp. 5-10(6)

Publisher: Blackwell Publishing

A Comparison of Costs among Patients with Type 2 Diabetes Mellitus Who Initiated Therapy with Exenatide or Insulin Glargine

Authors: Misurski, Derek; Lage, Maureen J.; Fabunmi, Rosalind; Boye, Kristina S.

Source: Applied Health Economics and Health Policy, Volume 7, Number 4, 1 December 2009 , pp. 245-254(10)

Publisher: Adis International

Cost Savings Associated with Filling a 3-Month Supply of Prescription Medicines

Authors: Rabbani, Atonu; Alexander, G. Caleb

Source: Applied Health Economics and Health Policy, Volume 7, Number 4, 1 December 2009 , pp. 255-264(10)

Publisher: Adis International

Fewer patients have forgone medication or basic needs because of drug costs since Medicare Part D was implemented in 2006

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 13-13(1)

Publisher: Adis International

Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences

Authors: Rappange, David R.; Brouwer, Werner B.F.; Hoogenveen, Rudolf T.; Van Baal, Pieter H.M.

Source: PharmacoEconomics, Volume 27, Number 12, 1 December 2009 , pp. 1031-1044(14)

Publisher: Adis International

Pharmacogenetics and Drug Development

Source: SourceOECD Science & Information Technology, Volume 2009, Number 19, November 2009 , pp. 35-51(17)

Publisher: OECD - Organisation for Economic Co-operation and Development

Pharmacogenetics and Drug Development

Source: SourceOECD Social Issues/Migration/Health, Volume 2009, Number 21, November 2009 , pp. 35-51(17)

Publisher: OECD - Organisation for Economic Co-operation and Development

Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence

Author: Carlson, Josh J

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 9, Number 5, October 2009 , pp. 409-416(8)

Publisher: Expert Reviews

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

Authors: Godman, Brian; Burkhardt, Thomas; Bucsics, Anna; Wettermark, Björn; Wieninger, Peter

Source: Expert Review of Pharmacoeconomics and Outcomes Research, Volume 9, Number 5, October 2009 , pp. 475-484(10)

Publisher: Expert Reviews

Doctors' attitudes about prescribing and knowledge of the costs of common medications

Authors: McGuire, C.; King, S.; Roche-Nagle, G.; Barry, M.

Source: Irish Journal of Medical Science, Volume 178, Number 3, September 2009 , pp. 277-280(4)

Publisher: Springer

Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand

Authors: Chainuvati, Siwaporn; Cheng, Jun; Hou, Jin; Hsu, Chao; Jia, Ji; Komolmit, Piyawat; Kwon, So; Lee, Chang; Li, Hong; Li, Ying; Liu, Chun; Neo, Boon; Peng, Cheng; Tanwandee, Tawesak; Wongcharatrawee, Suchat; Wu, Jaw; Yu, Ming; Zhang, Xin

Source: Hepatology International, Volume 3, Number 3, September 2009 , pp. 453-460(8)

Publisher: Springer